Photo: The Economic Times Markets
Business & Finance
US stocks: Summit shares drop after US FDA declines to approve lung cancer drug
TL;DR
- Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials.
Short summary
Our full write-up is on its way. For the complete story, read the original report:
Nov 16, 2026 · Updated 11/16/2026, 4:07:19 PM · Reported with: The Economic Times Markets
Sources (1)
NRI Bytes writes its own articles from the reporting below.
The Economic Times Markets — US stocks: Summit shares drop after US FDA declines to approve lung cancer drugUp next · Business & Finance
JPMorgan Warns Leveraged-Loan Defaults Set to Double in 2027
Read next →
More stories
Business & Finance
Treasuries’ Big Short Sets Up ‘Pain Trade’ as Haven Bid Ramps Up
1h ago
Business & Finance
Maryland’s $81 Billion Pension Is Slashing Hedge Funds to Zero
1h ago
Business & Finance
US yields ease as equities drop before Nvidia results
1h ago
Business & Finance
Like Rogers-Shaw, a Quebecor-Telus deal needs to sell Freedom too. But it won’t be enough
1h ago
Business & Finance
Apple says internal update caused outage as services recover
1h ago